Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A complete timeline of FDA label changes to Cialis (tadalafil) from 2020 through 2026, covering new safety warnings, revised dosing guidance, and post-market surveillance findings.
Read clinical reviewA complete regulatory history of Cialis (tadalafil), covering FDA approval, EMA authorization, generic entry, label updates, and global post-market surveillance data.
Read clinical reviewA side-by-side comparison of how the FDA and EMA approved, labeled, and monitor tadalafil (Cialis), including indication scope, dosing, safety signals, and post-market surveillance differences.
Read clinical reviewA clinical review of tadalafil (Cialis) compounding legality under FDA 503A and 503B frameworks, patent expiry implications, and how patients can safely access compounded tadalafil in 2026.
Read clinical reviewComplete history of Cialis (tadalafil) legal battles, patent disputes, FDA approval milestones, and regulatory actions from 2003 through generic entry.
Read clinical reviewA clinical review of tadalafil's FDA approval history, current label indications, post-market safety data, patent field, and next-generation PDE5 inhibitor pipeline developments.
Read clinical review